From Bench to Bedside: Targeting the IL-1β Pathway in Autoinflammatory Diseases

This symposium took place on 1st October 2015 as part  of ISSAID 2015: the International Society of Systemic Auto-inflammatory Diseases’ 8th International Congress of Familial Mediterranean Fever and Systemic Auto-inflammatory Diseases in Dresden, Germany

Chairperson: Gerd Horneff1
Speakers: Angelo Ravelli,2 Jasmin B Kümmerle-Deschner,3 Fabrizio De Benedetti4

1. Asklepios Clinic, Sankt Augustin, Germany
2. University of Genoa, Istituto Giannina Gaslini, Genoa, Italy
3. Division of Paediatric Rheumatology,  University Children’s Hospital Tübingen, Tübingen, Germany
4. Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy

Disclosure: Professor Gerd Horneff has received support for scientific projects and speakers’ fees from AbbVie, Pfizer, Roche, and Chugai, and has received speakers’ fees from Novartis. Professor Angelo Ravelli has received speakers’ or consultancy fees from AbbVie, Novartis, Pfizer, and Roche, and has received research grants from the American College of Rheumatology/European League Against Rheumatism  (ACR/EULAR), Agenzia Italiana del Farmaco (AIFA), and Pfizer. Doctor Jasmin B Kümmerle-Deschner has received support for scientific projects from Novartis and speakers’ or consultancy fees from Novartis and SOBI. Professor Fabrizio De Benedetti has received unrestricted research grants from AbbVie, BMS,  Novartis, Novimmune, Pfizer, and Roche.
Acknowledgements: Writing assistance was provided by Dr Lynda McEvoy, ApotheCom Ltd.
Support: The publication of this article was funded by Novartis. The views and opinions expressed are  those of the authors and not necessarily of Novartis.
Citation: EMJ Rheumatol. 2016;3(Suppl 4):2–10.

Meeting Summary

Prof Gerd Horneff opened the symposium with a summary of the recent advances in the understanding of the role of interleukin (IL)-1β in the pathogenesis of autoinflammatory (AI) diseases. Prof Angelo Ravelli then discussed the concept of ‘treat-to-target’ in systemic juvenile idiopathic arthritis (SJIA) and the  various tools that can be used for monitoring treatment response. Dr Jasmin B Kümmerle-Deschner  followed with an overview of the efficacy and safety data from the β-Confident Registry of patients with cryopyrin-associated periodic syndromes (CAPS) receiving treatment with canakinumab. Prof Fabrizio De Benedetti concluded with an overview of the up-and-coming data in the field of AI diseases. The objectives of the symposium were to summarise new insights in the pathogenesis of AI diseases including the role of IL-1β; to evaluate the use of anti-IL-1β and other treatment options for AI diseases; to describe the  treat-to-target concept and recognise the potential of a tight disease control strategy in patients with  SJIA; to integrate new knowledge on the long-term use of canakinumab in patients with CAPS based on  the latest β-Confident Registry data; and to discuss management strategies in patients with AI diseases.

Download (PDF, 135KB)

Keywords:

Comments are closed.